Seaport Therapeutics Reports Q2 Progress Across Neuropsychiatry Pipeline
BOSTON, Aug. 3, 2026 Seaport Therapeutics, Inc. reported its second-quarter 2026 financial results while highlighting continued progress across its...
Borrelia burgdorferi
Advertisement
Biocon Launches Yesafili Biosimilar to Eylea in U.S.
BENGALURU, India, and BRIDGEWATER, N.J., Aug. 3, 2026 Biocon Limited has announced the U.S. commercial launch of Yesafili™ (aflibercept-jbvf),...
Can-Fite Launches Phase 2 Piclidenoson Trial for Lowe Syndrome
RAMAT GAN, Israel, Aug. 3, 2026 Can-Fite BioPharma Ltd. has launched its first clinical development program evaluating Piclidenoson for...
Opus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trial
RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2026 Opus Genetics, Inc. has completed patient enrollment in its registrational Phase 3...
Tonix Pharmaceuticals Receives FDA Alignment for TNX-4800 Phase 2 Trial
BERKELEY HEIGHTS, N.J., Aug. 3, 2026 Tonix Pharmaceuticals Holding Corp. announced that it has received official Type C meeting...
Advertisement
